Editorial
doi: 10.1158/1078-0432.CCR-04-0922.
Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era
- PMID: 15328164
- DOI: 10.1158/1078-0432.CCR-04-0922
Item in Clipboard
Editorial
Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era
Clin Cancer Res.
.
No abstract available
Comment on
-
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.Clin Cancer Res. 2004 Aug 15;10(16):5327-34. doi: 10.1158/1078-0432.CCR-04-0294. Clin Cancer Res. 2004. PMID: 15328168 Clinical Trial.
Similar articles
-
Rituximab plus CHOP for diffuse large-B-cell lymphoma.N Engl J Med. 2002 Jun 6;346(23):1830-1; author reply 1830-1. doi: 10.1056/NEJM200206063462317. N Engl J Med. 2002. PMID: 12050349 No abstract available.
-
CHOP and rituximab in elderly patients.Curr Oncol Rep. 2002 Sep;4(5):414. Curr Oncol Rep. 2002. PMID: 12162916 Clinical Trial. No abstract available.
-
Rituximab for the treatment of diffuse large B-cell lymphomas.Expert Rev Anticancer Ther. 2006 Aug;6(8):1175-86. doi: 10.1586/14737140.6.8.1175. Expert Rev Anticancer Ther. 2006. PMID: 16925484 Review.
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.J Clin Oncol. 2005 Aug 1;23(22):5027-33. doi: 10.1200/JCO.2005.09.137. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955905
-
The therapeutic use of rituximab in non-Hodgkin's lymphoma.Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x. Eur J Haematol Suppl. 2007. PMID: 17206982 Review.
Cited by
-
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.Curr Hematol Malig Rep. 2008 Oct;3(4):187-93. doi: 10.1007/s11899-008-0027-5. Curr Hematol Malig Rep. 2008. PMID: 20425465 Review.
-
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.Curr Treat Options Oncol. 2006 Jul;7(4):276-84. doi: 10.1007/s11864-006-0037-2. Curr Treat Options Oncol. 2006. PMID: 16916488 Review.
-
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.Br J Haematol. 2009 Aug;146(3):282-91. doi: 10.1111/j.1365-2141.2009.07773.x. Epub 2009 Jun 10. Br J Haematol. 2009. PMID: 19519691 Free PMC article. Clinical Trial.
-
Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.Curr Oncol Rep. 2008 Sep;10(5):420-6. doi: 10.1007/s11912-008-0064-1. Curr Oncol Rep. 2008. PMID: 18706270 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
